{"id":22735,"date":"2021-05-17T09:15:00","date_gmt":"2021-05-17T13:15:00","guid":{"rendered":"https:\/\/www.cancerresearch.org\/2021\/05\/covid-19-impact-oncology-clinical-trials-2020-2021\/"},"modified":"2022-08-28T23:15:16","modified_gmt":"2022-08-29T03:15:16","slug":"covid-19-impact-oncology-clinical-trials-2020-2021","status":"publish","type":"post","link":"https:\/\/www.cancerresearch.org\/es\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021","title":{"rendered":"Impacto de la pandemia de COVID-19 en los ensayos cl\u00ednicos oncol\u00f3gicos: an\u00e1lisis de seguimiento a un a\u00f1o\ufffc"},"content":{"rendered":"\n<p>La pandemia de COVID-19 repercuti\u00f3 en todos los aspectos de la vida cotidiana: alter\u00f3 las rutinas, nos distanci\u00f3 de los seres queridos y gener\u00f3 muchas dudas sobre la seguridad en medio de tanta incertidumbre. La atenci\u00f3n m\u00e9dica tambi\u00e9n se vio afectada y muchas personas postergaron sus controles m\u00e9dicos de rutina o evitaron los tratamientos previstos ante sus temores acerca del COVID-19.<\/p>\n\n\n\n<p>A\u00fan no se conocen por completo las consecuencias de la pandemia de COVID-19 en\u00a0la incidencia y mortalidad por c\u00e1ncer, pero los investigadores prev\u00e9n que repercutir\u00e1n en las tendencias generales. Uno de los principales aspectos que deben medirse es el impacto del COVID-19 en los ensayos cl\u00ednicos de c\u00e1ncer en el mundo. Un equipo del Cancer Research Institute (CRI) realiz\u00f3 el seguimiento de esta consecuencia desde que se instal\u00f3 la pandemia, a principios de 2020, y hoy public\u00f3 un\u00a0<a rel=\"noopener\" href=\"https:\/\/www.nature.com\/articles\/d41573-021-%2000086-8\" target=\"_blank\">informe de seguimiento a un a\u00f1o del an\u00e1lisis anterior<\/a>\u00a0en\u00a0<em>Nature Reviews Drug Discovery<\/em>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg\" alt=\"\" class=\"wp-image-19598\" srcset=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg 1024w, https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-300x157.jpg 300w, https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-768x402.jpg 768w, https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook.jpg 1200w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>El an\u00e1lisis reci\u00e9n publicado del CRI revel\u00f3 que se redujo el impacto de la pandemia de COVID-19 en los ensayos cl\u00ednicos oncol\u00f3gicos a nivel mundial, con m\u00e1s ensayos suspendidos que se retomaron a un ritmo m\u00e1s r\u00e1pido que los ensayos no oncol\u00f3gicos. El informe tambi\u00e9n muestra que esta tasa positiva de reactivaci\u00f3n se observ\u00f3 en los estudios cl\u00ednicos de intervenci\u00f3n que probaban nuevos m\u00e9todos terap\u00e9uticos, independientemente del tipo de tumor o de tratamiento. En resumen, los ensayos cl\u00ednicos de c\u00e1ncer se vieron menos afectados por la pandemia de COVID-19 que los ensayos centrados en otros problemas de salud, y aparentemente se est\u00e1n abriendo para pacientes a un ritmo cada vez mayor en comparaci\u00f3n con esta \u00e9poca del a\u00f1o pasado.<\/p>\n\n\n\n<p>El informe del CRI muestra que la cantidad de ensayos cl\u00ednicos que figuran en clinicaltrials.gov y que se interrumpieron debido a la pandemia de COVID-19 alcanz\u00f3 su punto m\u00e1ximo en junio de 2020, mientras que la suspensi\u00f3n o cese de los ensayos oncol\u00f3gicos alcanz\u00f3 su punto m\u00e1ximo un mes antes, en mayo. Un total de 386 ensayos cl\u00ednicos oncol\u00f3gicos se vieron afectados, de los cuales 274 se reactivaron (71 %), 74 permanecen suspendidos, 27 se interrumpieron y 11 se cancelaron. El porcentaje de ensayos reactivados marca un gran contraste con los 1665 ensayos no oncol\u00f3gicos afectados por la pandemia, de los cuales 665 se reanudaron (40 %), 605 permanecen suspendidos, 287 se interrumpieron y 108 se cancelaron.<\/p>\n\n\n\n<p>No solo la investigaci\u00f3n cl\u00ednica se vio perjudicada con la interrupci\u00f3n de ensayos, sino tambi\u00e9n la atenci\u00f3n a pacientes: se perdieron 1155 cupos oncol\u00f3gicos previstos debido a estudios interrumpidos y cancelados. El cierre de laboratorios y el cambio de prioridades probablemente retrasaron la evoluci\u00f3n de los ensayos cl\u00ednicos. No obstante, la mayor\u00eda de los ensayos oncol\u00f3gicos reactivados se suspendieron por menos de tres meses y los estudios cl\u00ednicos de intervenci\u00f3n se reanudaron m\u00e1s r\u00e1pido que los estudios de observaci\u00f3n. Los ensayos oncol\u00f3gicos que no se reanudaron durante el per\u00edodo analizado siguen suspendidos. Los 74 ensayos oncol\u00f3gicos que siguen suspendidos representan m\u00e1s de 99 940 cupos previstos para pacientes. El tipo de tratamiento en estudio y el c\u00e1ncer al que apunta no parecen ser factores que afecten la reactivaci\u00f3n de un ensayo. La mayor\u00eda de los ensayos oncol\u00f3gicos detenidos implicaban c\u00e1nceres de tumores s\u00f3lidos, y el c\u00e1ncer de mama represent\u00f3 el 18 por ciento de estos estudios.<\/p>\n\n\n\n<p>En el informe del Cancer Research Institute se indica que la pandemia de COVID-19 tuvo menos impacto en la interrupci\u00f3n, cancelaci\u00f3n y suspensi\u00f3n de los ensayos cl\u00ednicos oncol\u00f3gicos que de los no oncol\u00f3gicos. Cabe destacar que el n\u00famero de ensayos cl\u00ednicos no oncol\u00f3gicos suspendidos debido al COVID-19 aument\u00f3 ligeramente en los \u00faltimos cinco meses, un indicio de que la lucha mundial por contener este virus a\u00fan no ha terminado. Sin embargo, los analistas del CRI esperan que el efecto continuo de la pandemia en todos los ensayos se reduzca a medida que aumenta el ritmo de vacunaci\u00f3n a nivel mundial.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new CRI report highlights the impact of the COVID-19 pandemic on cancer clinical trials compared to non-cancer trials.<\/p>\n","protected":false},"author":26,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[377],"tags":[401,394,402,399],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-22735","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar","tag-clinical-accelerator-es","tag-clinical-trials-es","tag-covid-19-es","tag-research-es"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>COVID-19\u2019s Impact on Oncology Clinical Trials: A One-Year Follow-Up Analysis<\/title>\n<meta name=\"description\" content=\"The newly published analysis from CRI revealed that the impact of the COVID-19 pandemic on oncology clinical trials globally has diminished, with more paused trials restarted at faster rates than non-oncology trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19\u2019s Impact on Oncology Clinical Trials: A One-Year Follow-Up Analysis\" \/>\n<meta property=\"og:description\" content=\"The newly published analysis from CRI revealed that the impact of the COVID-19 pandemic on oncology clinical trials globally has diminished, with more paused trials restarted at faster rates than non-oncology trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-17T13:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-29T03:15:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg\" \/>\n<meta name=\"author\" content=\"Robert Levine\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Robert Levine\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021\"},\"author\":{\"name\":\"Robert Levine\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/person\/7a4a7e3224ee5e9ecc01e9575cb5ce7c\"},\"headline\":\"Impacto de la pandemia de COVID-19 en los ensayos cl\u00ednicos oncol\u00f3gicos: an\u00e1lisis de seguimiento a un a\u00f1o\ufffc\",\"datePublished\":\"2021-05-17T13:15:00+00:00\",\"dateModified\":\"2022-08-29T03:15:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021\"},\"wordCount\":723,\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg\",\"keywords\":[\"clinical accelerator\",\"clinical trials\",\"COVID-19\",\"research\"],\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021\",\"url\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021\",\"name\":\"COVID-19\u2019s Impact on Oncology Clinical Trials: A One-Year Follow-Up Analysis\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg\",\"datePublished\":\"2021-05-17T13:15:00+00:00\",\"dateModified\":\"2022-08-29T03:15:16+00:00\",\"description\":\"The newly published analysis from CRI revealed that the impact of the COVID-19 pandemic on oncology clinical trials globally has diminished, with more paused trials restarted at faster rates than non-oncology trials.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Impacto de la pandemia de COVID-19 en los ensayos cl\u00ednicos oncol\u00f3gicos: an\u00e1lisis de seguimiento a un a\u00f1o\ufffc\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/person\/7a4a7e3224ee5e9ecc01e9575cb5ce7c\",\"name\":\"Robert Levine\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0604bad1c41d52a90e9b4639bf17147f972c8d0a9d43a5d3bed8cb2274ef0410?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0604bad1c41d52a90e9b4639bf17147f972c8d0a9d43a5d3bed8cb2274ef0410?s=96&d=mm&r=g\",\"caption\":\"Robert Levine\"},\"url\":\"https:\/\/www.cancerresearch.org\/es\/blog\/author\/rlevine\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COVID-19\u2019s Impact on Oncology Clinical Trials: A One-Year Follow-Up Analysis","description":"The newly published analysis from CRI revealed that the impact of the COVID-19 pandemic on oncology clinical trials globally has diminished, with more paused trials restarted at faster rates than non-oncology trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021","og_locale":"es_ES","og_type":"article","og_title":"COVID-19\u2019s Impact on Oncology Clinical Trials: A One-Year Follow-Up Analysis","og_description":"The newly published analysis from CRI revealed that the impact of the COVID-19 pandemic on oncology clinical trials globally has diminished, with more paused trials restarted at faster rates than non-oncology trials.","og_url":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021","og_site_name":"Cancer Research Institute","article_published_time":"2021-05-17T13:15:00+00:00","article_modified_time":"2022-08-29T03:15:16+00:00","og_image":[{"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg","type":"","width":"","height":""}],"author":"Robert Levine","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Robert Levine","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#article","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021"},"author":{"name":"Robert Levine","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/person\/7a4a7e3224ee5e9ecc01e9575cb5ce7c"},"headline":"Impacto de la pandemia de COVID-19 en los ensayos cl\u00ednicos oncol\u00f3gicos: an\u00e1lisis de seguimiento a un a\u00f1o\ufffc","datePublished":"2021-05-17T13:15:00+00:00","dateModified":"2022-08-29T03:15:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021"},"wordCount":723,"publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"image":{"@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg","keywords":["clinical accelerator","clinical trials","COVID-19","research"],"articleSection":["Sin categorizar"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021","url":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021","name":"COVID-19\u2019s Impact on Oncology Clinical Trials: A One-Year Follow-Up Analysis","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg","datePublished":"2021-05-17T13:15:00+00:00","dateModified":"2022-08-29T03:15:16+00:00","description":"The newly published analysis from CRI revealed that the impact of the COVID-19 pandemic on oncology clinical trials globally has diminished, with more paused trials restarted at faster rates than non-oncology trials.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/CA_landscape_facebook-1024x536.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/blog\/covid-19-impact-oncology-clinical-trials-2020-2021#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Impacto de la pandemia de COVID-19 en los ensayos cl\u00ednicos oncol\u00f3gicos: an\u00e1lisis de seguimiento a un a\u00f1o\ufffc"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/person\/7a4a7e3224ee5e9ecc01e9575cb5ce7c","name":"Robert Levine","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0604bad1c41d52a90e9b4639bf17147f972c8d0a9d43a5d3bed8cb2274ef0410?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0604bad1c41d52a90e9b4639bf17147f972c8d0a9d43a5d3bed8cb2274ef0410?s=96&d=mm&r=g","caption":"Robert Levine"},"url":"https:\/\/www.cancerresearch.org\/es\/blog\/author\/rlevine"}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/posts\/22735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/comments?post=22735"}],"version-history":[{"count":0,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/posts\/22735\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=22735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/categories?post=22735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tags?post=22735"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=22735"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=22735"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=22735"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=22735"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=22735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}